Themis Bioscience
Biotechnology company that developed novel vaccines for high burden infectious diseases and oncology applications using a measles virus vector platform. Acquired by Merck in 2020.
Location
Vienna, Austria
Founded
2009
Investors
1
Categories
vaccines, infectious-disease, oncology, biotech, acquired
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Adjuvant Capital | Washington, DC, USA | biotech-focused | seedseries-a+3 | 16 |